Mesenchymal Stem Cell Therapy Market Size, Share & Trends Analysis Report By Type (Autologous, Allogenic), By Source (Bone Marrow, Umbilical Cord, Adipose), By Disease Indication, By Region, And Segment Forecasts, 2025

The global mesenchymal stem cell therapy market size is anticipated to reach USD 296.6 million by 2030 and is projected to grow at a CAGR of 23.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The mesenchymal stem cell (MSC) therapy market is experiencing significant growth, driven by several key factors. One major driver is the increasing prevalence of chronic diseases such as cardiovascular conditions, diabetes, autoimmune disorders, and orthopedic ailments. MSCs possess unique regenerative and immunomodulatory properties, making them promising candidates for treating these chronic conditions. Their ability to differentiate into various cell types and promote tissue repair has spurred interest in MSC-based therapeutics. As the global burden of chronic illnesses continues to rise, the demand for innovative treatments like MSC therapy is expected to grow correspondingly.

Another significant factor propelling the MSC therapy market is the growing awareness and advancement in regenerative medicine. Regenerative medicine focuses on repairing or replacing damaged cells, tissues, or organs, and MSCs play a crucial role due to their multipotent nature. The field has witnessed a surge in clinical trials and research activities, aiming to harness the potential of MSCs in various therapeutic applications. This heightened focus on regenerative solutions is contributing to the expansion of the MSC therapy market.

Technological advancements have also been instrumental in driving the MSC therapy market forward. Innovations in stem cell isolation, culture, and manipulation techniques have enhanced the efficiency and effectiveness of MSC therapies. The development of Good Manufacturing Practice (GMP)-compliant products ensures consistent quality and safety, facilitating broader clinical adoption. These technological strides not only improve existing treatments but also open new avenues for therapeutic applications, thereby increasing the overall demand for MSC therapies.

Furthermore, the MSC therapy market benefits from a supportive regulatory environment and increased funding for stem cell research. Governments and institutions are implementing policies that facilitate clinical trials and expedite approvals for new stem cell treatments. This favorable landscape encourages innovation and allows for the efficient development and commercialization of MSC therapies. Additionally, heightened investment from both public and private sectors fosters research initiatives and collaborations, ensuring a steady pipeline of new MSC treatments.

Mesenchymal Stem Cell Therapy Market Report Highlights:

Based on type, allogenic segment dominated the overall market with the largest revenue share of 73.83% in 2024 and is expected to grow at the fastest CAGR during the forecast period. The increasing use of allogenic mesenchymal stem cells (MSCs) in therapy is driving market growth due to their ability to be sourced from healthy donors and applied to multiple patients. This reduces the need for personalized cell sourcing, making treatments more accessible and cost-effective.
Based on source, the adipose segment dominated the overall market with the largest revenue share of 37.71% in 2024 and is expected to grow at the fastest CAGR during the forecast period. The market for adipose-derived stem cells (ADSCs) is expanding due to their high yield and multipotency, offering effective treatments for various chronic diseases and age-related conditions. Ongoing advancements in cell processing and manufacturing techniques are enhancing the accessibility and affordability of ADSC therapies, further driving market growth.
In 2024, orthopedic and musculoskeletal disorders segment held the second-largest market share of 25.56% in the disease indication segment. As the burden of musculoskeletal diseases rises globally, the orthopedic segment continues to be a major growth area within the MSC therapy landscape.
Asia Pacific accounted for the largest market share of 71.56% in 2024. The market is experiencing rapid growth fueled by government support, rising healthcare investments, and increasing local clinical activity.

Product Code: GVR-4-68040-554-9

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
- 1.2.1. Type
- 1.2.2. Source
- 1.2.3. Disease Indication
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
- 1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
- 3.3.1. Market Driver Analysis
  - 3.3.1.1. Broad Therapeutic Potential Across Multiple Diseases
  - 3.3.1.2. Advancements in Cell Culture & Manufacturing Technologies
- 3.3.2. Market Restraint Analysis
  - 3.3.2.1. Stringent Regulatory Frameworks
3.4. Industry Analysis Tools
- 3.4.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
- 3.4.2. Porter's Five Forces Analysis
- 3.4.3. COVID-19 Impact Analysis

Chapter 4. Mesenchymal Stem Cell Therapy Market: Type Business Analysis

4.1. Segment Dashboard
4.2. Global Mesenchymal Stem Cell Therapy Movement Analysis
4.3. Global Mesenchymal Stem Cell Therapy Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Autologous
- 4.4.1. Global Autologous Market, 2018 - 2030 (USD Million)
4.5. Allogenic
- 4.5.1. Global Allogenic Market, 2018 - 2030 (USD Million)

Chapter 5. Mesenchymal Stem Cell Therapy Market: Source Business Analysis

5.1. Segment Dashboard
5.2. Global Mesenchymal Stem Cell Therapy Movement Analysis
5.3. Global Mesenchymal Stem Cell Therapy Market Size & Trend Analysis, by Source, 2018 to 2030 (USD Million)
5.4. Bone Marrow
- 5.4.1. Global Bone Marrow Market, 2018 - 2030 (USD Million)
5.5. Umbilical Cord
- 5.5.1. Global Umbilical Cord Market, 2018 - 2030 (USD Million)
5.6. Adipose
- 5.6.1. Global Adipose Market, 2018 - 2030 (USD Million)
5.7. Others Sources
- 5.7.1. Global Others Sources Market, 2018 - 2030 (USD Million)

Chapter 6. Mesenchymal Stem Cell Therapy Market: Disease Indication Business Analysis

6.1. Segment Dashboard
6.2. Global Mesenchymal Stem Cell Therapy Movement Analysis
6.3. Global Mesenchymal Stem Cell Therapy Market Size & Trend Analysis, by Disease Indication, 2018 to 2030 (USD Million)
6.4. Orthopedic and Musculoskeletal Disorders
- 6.4.1. Global Orthopedic and Musculoskeletal Disorders Market, 2018 - 2030 (USD Million)
6.5. Cardiovascular Diseases
- 6.5.1. Global Cardiovascular Diseases Market, 2018 - 2030 (USD Million)
6.6. Neurological and CNS Disorders
- 6.6.1. Global Neurological and CNS Disorders Market, 2018 - 2030 (USD Million)
6.7. Hematological / Immune Disorders
- 6.7.1. Global Hematological / Immune Disorders Market, 2018 - 2030 (USD Million)
6.8. Others Indications
- 6.8.1. Global Others Indications Market, 2018 - 2030 (USD Million)

Chapter 7. Mesenchymal Stem Cell Therapy Market: Regional Estimates & Trend Analysis by Type, Source, Disease Indication

7.1. Regional Dashboard
7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
7.3. North America
- 7.3.1. North America Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. U.S.
  - 7.3.2.1. Key Country Dynamics
  - 7.3.2.2. Competitive Scenario
  - 7.3.2.3. Regulatory Framework
  - 7.3.2.4. U.S. Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Europe
- 7.4.1. Europe Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. UK
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Competitive Scenario
  - 7.4.2.3. Regulatory Framework
  - 7.4.2.4. UK Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Germany
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Competitive Scenario
  - 7.4.3.3. Regulatory Framework
  - 7.4.3.4. Germany Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Asia Pacific
- 7.5.1. Asia Pacific Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Japan
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Competitive Scenario
  - 7.5.2.3. Regulatory Framework
  - 7.5.2.4. Japan Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. South Korea
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Competitive Scenario
  - 7.5.3.3. Regulatory Framework
  - 7.5.3.4. South Korea Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Rest of World
- 7.6.1. Rest of World Mesenchymal Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Company/Competition Categorization
8.2. Strategy Mapping
8.3. Company Position Analysis, 2024
8.4. Company Profiles/Listing
- 8.4.1. MEDIPOST, Inc.
  - 8.4.1.1. Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Strategic Initiatives
- 8.4.2. PHARMICELL Co., Ltd
  - 8.4.2.1. Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Strategic Initiatives
- 8.4.3. Antrogen
  - 8.4.3.1. Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Strategic Initiatives
- 8.4.4. CORESTEMCHEMON Inc.
  - 8.4.4.1. Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Strategic Initiatives
- 8.4.5. NIPRO Corporation
  - 8.4.5.1. Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Strategic Initiatives
- 8.4.6. STEMPEUTICS RESEARCH PVT LTD
  - 8.4.6.1. Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Strategic Initiatives
- 8.4.7. JCR Pharmaceuticals Co Ltd
  - 8.4.7.1. Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Strategic Initiatives
- 8.4.8. Mesoblast, Inc.
  - 8.4.8.1. Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Strategic Initiatives
- 8.4.9. Cell Tech Pharmed
  - 8.4.9.1. Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Strategic Initiatives
- 8.4.10. HOLOSTEM S.r.l.
  - 8.4.10.1. Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Strategic Initiatives
- 8.4.11. Takeda Pharmaceutical Company Limited
  - 8.4.11.1. Overview
  - 8.4.11.2. Financial Performance
  - 8.4.11.3. Product Benchmarking
  - 8.4.11.4. Strategic Initiatives

Product Code: GVR-4-68040-554-9

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
Table 4 Global mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
Table 5 Global mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 6 Global mesenchymal stem cell therapy market, by region, 2018 - 2030 (USD Million)
Table 7 North America mesenchymal stem cell therapy market, by country, 2018 - 2030 (USD Million)
Table 8 North America mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
Table 9 North America mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
Table 10 North America mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 11 U.S. mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
Table 12 U.S. mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
Table 13 U.S. mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 14 Europe mesenchymal stem cell therapy market, by country, 2018 - 2030 (USD Million)
Table 15 Europe mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
Table 16 Europe mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
Table 17 Europe mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 18 UK mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
Table 19 UK mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
Table 20 UK mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 21 Germany mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
Table 22 Germany mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
Table 23 Germany mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 24 Asia Pacific mesenchymal stem cell therapy market, by country, 2018 - 2030 (USD Million)
Table 25 Asia Pacific mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
Table 26 Asia Pacific mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
Table 27 Asia Pacific mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 28 Japan mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
Table 29 Japan mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
Table 30 Japan mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 31 South Korea mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
Table 32 South Korea mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
Table 33 South Korea mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 34 Rest of World mesenchymal stem cell therapy market, by country, 2018 - 2030 (USD Million)
Table 35 Rest of World mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
Table 36 Rest of World mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
Table 37 Rest of World mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 38 Participant's overview
Table 39 Financial performance
Table 40 Key companies undergoing expansions
Table 41 Key companies undergoing acquisitions
Table 42 Key companies undergoing collaborations
Table 43 Key companies launching new products
Table 44 Key companies undertaking other strategies

List of Figures

Fig. 1 Mesenchymal stem cell therapy market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Parent market outlook
Fig. 13 Related/ancillary market outlook
Fig. 14 Genomics - Industry value chain analysis
Fig. 15 Mesenchymal stem cell therapy market driver analysis
Fig. 16 Mesenchymal stem cell therapy market restraint analysis
Fig. 17 Mesenchymal stem cell therapy market: Porter's analysis
Fig. 18 Mesenchymal stem cell therapy market: Type outlook and key takeaways
Fig. 19 Mesenchymal stem cell therapy market: Type market share analysis, 2023 - 2030
Fig. 20 Global mesenchymal stem cell therapy by autologous market, 2018 - 2030 (USD Million)
Fig. 21 Global mesenchymal stem cell therapy by allogenic market, 2018 - 2030 (USD Million)
Fig. 22 Mesenchymal stem cell therapy market: Source outlook and key takeaways
Fig. 23 Mesenchymal stem cell therapy market: Source market share analysis, 2023 - 2030
Fig. 24 Global mesenchymal stem cell therapy by umbilical cord market, 2018 - 2030 (USD Million)
Fig. 25 Global mesenchymal stem cell therapy by adipose market, 2018 - 2030 (USD Million)
Fig. 26 Global mesenchymal stem cell therapy by other sources market, 2018 - 2030 (USD Million)
Fig. 27 Mesenchymal stem cell therapy market: Disease indication outlook and key takeaways
Fig. 28 Mesenchymal stem cell therapy market: Disease indication market share analysis, 2023 - 2030
Fig. 29 Global mesenchymal stem cell therapy by orthopedic and musculoskeletal disorders market, 2018 - 2030 (USD Million)
Fig. 30 Global mesenchymal stem cell therapy by cardiovascular diseases market, 2018 - 2030 (USD Million)
Fig. 31 Global mesenchymal stem cell therapy by neurological and CNS disorders market, 2018 - 2030 (USD Million)
Fig. 32 Global mesenchymal stem cell therapy by hematological / immune disorders market, 2018 - 2030 (USD Million)
Fig. 33 Global mesenchymal stem cell therapy by other indications market, 2018 - 2030 (USD Million)
Fig. 34 Regional marketplace: Key takeaways
Fig. 35 North America mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 U.S. key country dynamics
Fig. 37 U.S. mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Europe mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 UK key country dynamics
Fig. 40 UK mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Germany key country dynamics
Fig. 42 Germany mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Asia-Pacific mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Japan key country dynamics
Fig. 45 Japan mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 South Korea key country dynamics
Fig. 47 South Korea mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Rest of World mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Key company categorization
Fig. 50 Company market positioning
Fig. 51 Market participant categorization
Fig. 52 Strategy framework

Mesenchymal Stem Cell Therapy Market Size, Share & Trends Analysis Report By Type (Autologous, Allogenic), By Source (Bone Marrow, Umbilical Cord, Adipose), By Disease Indication, By Region, And Segment Forecasts, 2025 - 2030

Description

Table of Contents

List of Tables

Mesenchymal Stem Cell Therapy Market Growth & Trends:

Mesenchymal Stem Cell Therapy Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. Mesenchymal Stem Cell Therapy Market: Type Business Analysis

Chapter 5. Mesenchymal Stem Cell Therapy Market: Source Business Analysis

Chapter 6. Mesenchymal Stem Cell Therapy Market: Disease Indication Business Analysis

Chapter 7. Mesenchymal Stem Cell Therapy Market: Regional Estimates & Trend Analysis by Type, Source, Disease Indication

Chapter 8. Competitive Landscape

List of Tables

List of Figures